verified SJR 7,283 · Q1 • database Scopus / SJR & Web of Science indexed

United States · American Association for Can...

workspace_premium Q1 — Oncology lock Subscription Unclaimed

Cancer Discovery

Cancer Discovery is a journal indexed in SJR in Oncology with an H index of 250. It has a price of 4524 €. It has an SJR impact factor of 7,283 and it has a best quartile of Q1. It has an SJR impact factor of 7,283.

Cancer Discovery focuses its scope in these topics and keywords: inhibitor, cells, tumor, pancreatic, dna, anticancer, entry, expression, ferroptosisqa, fusion, ...

ISSN: 2159-8274

Editorial: American Association for Cancer Research Inc.

Category: Oncology

Indexation: verifiedScopus / SJR verifiedWeb of Science

Unclaimed profile — some fields may be incomplete.

open_in_new Portal NPD menu_book Guidelines NPD

schedule Datos CoP · solo campos en BD

SJR Impact Factor trending_up

7,283 Q1

H-index 250

Tasa de Aceptación pie_chart

20% Selectiva

Fuente Acceptance_Rate

Tiempo a publicación hourglass_top

NPD

Campo Sin dato

Coste de Publicación (APC) payments

4.524 € Subscription

Ruta Non-OA 2262 €

Metrics

Campos Scimago / CoP — sin series inventadas

Scopus / SJR Web of Science

SJR Impact

7,283

H-index

250

Docs (year)

215

Docs 3y

1311

Total refs

8687

Cites 3y

14180

Citable 3y

1125

Cites/Doc 2y

10.53

Ref/Doc

40.4

Immediate OA

4524 €

Embargoed OA

NPD

Non OA / Submission

2262 €

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims

rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID * * Only to validate authenticity — identity is not shown publicly.

Best articles by citations

Large-Scale Drug Screens Support Precision Medicine

YAP Is Essential for Treg-Mediated Suppression of Antitumor Immunity

Tumor-Promoting and -Suppressive Roles of Autophagy in the Same Mouse Model of BrafV600E-Driven Lung Cancer

Tumor microenvironment is critical for the maintenance of cellular states found in primary glioblastomas.

Targeting Apoptosis: A New Paradigm for the Treatment of Estrogen Receptor-Positive Breast Cancer

SPSB1 May Have MET Its Match during Breast Cancer Recurrence

Social Interactomes for Enabling Research Communities

Recurrent Tumor Cell-Intrinsic and -Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation

Predicting Cancer Drug Response: Advancing the DREAM

Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells

Optimizing Next-Generation AML Therapy: Activity of Mutant IDH2 Inhibitor AG-221 in Preclinical Models

Lifting Up the HAT: Synthetic Lethal Screening Reveals a Novel Vulnerability at the CBP-p300 Axis

SHOW MORE ARTICLES

A Little pRB Can Lead to Big Problems

Insights into the Mechanism of Organ-Specific Cancer Metastasis

Insights into Epigenetic Remodeling in VHL-Deficient Clear Cell Renal Cell Carcinoma

Infant high grade gliomas comprise multiple subgroups characterized by novel targetable gene fusions and favorable outcomes

Haploinsufficiency of an RB-E2F1-Condensin II Complex Leads to Aberrant Replication and Aneuploidy

Gain-of-function genetic alterations of G9a drive oncogenesis

First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study

Escaping Out of the Brain

Dual MAPK/CDK Targeting in Melanoma: New Approaches, New Challenges

Collateral Genome Instability by DNA Damage in Mitosis

BluepRINT for Moderate-to-Low Penetrance Cancer Susceptibility Genes Needed: Breast Cancer and Beyond

Adenoid Cystic Carcinoma Can Be Driven by MYB or MYBL1 Rearrangements: New Insights into MYB and Tumor Biology

FAQS

In Country of Papers you can find SJR impact factor and other metrics to help you decide on a Journal.